Publication Information

{'id': 'https://openalex.org/W2976394260', 'doi': None, 'title': 'Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.', 'display_name': 'Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.', 'publication_year': 2017, 'publication_date': '2017-10-01', 'ids': {'openalex': 'https://openalex.org/W2976394260', 'mag': '2976394260', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/28991932'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28991932', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5111780435', 'display_name': 'Steve Edelman', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210132395', 'display_name': 'University of California San Diego Medical Center', 'ror': 'https://ror.org/03aw5sn18', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800935791', 'https://openalex.org/I4210132395']}], 'countries': ['US'], 'is_corresponding': True, 'raw_author_name': 'Steve V Edelman', 'raw_affiliation_strings': ['Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California, USA.'], 'affiliations': [{'raw_affiliation_string': 'Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California, USA.', 'institution_ids': ['https://openalex.org/I4210132395']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5111780435'], 'corresponding_institution_ids': ['https://openalex.org/I4210132395'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 63}, 'biblio': {'volume': '66', 'issue': '10 Suppl', 'first_page': 'S12', 'last_page': 'S16'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10401', 'display_name': 'Diabetes Treatment and Management', 'score': 0.9947, 'subfield': {'id': 'https://openalex.org/subfields/2712', 'display_name': 'Endocrinology, Diabetes and Metabolism'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10401', 'display_name': 'Diabetes Treatment and Management', 'score': 0.9947, 'subfield': {'id': 'https://openalex.org/subfields/2712', 'display_name': 'Endocrinology, Diabetes and Metabolism'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/lixisenatide', 'display_name': 'Lixisenatide', 'score': 0.9476811}, {'id': 'https://openalex.org/keywords/dulaglutide', 'display_name': 'Dulaglutide', 'score': 0.9371843}, {'id': 'https://openalex.org/keywords/semaglutide', 'display_name': 'Semaglutide', 'score': 0.9043381}], 'concepts': [{'id': 'https://openalex.org/C2780533449', 'wikidata': 'https://www.wikidata.org/wiki/Q417762', 'display_name': 'Exenatide', 'level': 4, 'score': 0.9769958}, {'id': 'https://openalex.org/C2781308992', 'wikidata': 'https://www.wikidata.org/wiki/Q2526479', 'display_name': 'Liraglutide', 'level': 4, 'score': 0.95264184}, {'id': 'https://openalex.org/C2776442814', 'wikidata': 'https://www.wikidata.org/wiki/Q6659956', 'display_name': 'Lixisenatide', 'level': 5, 'score': 0.9476811}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9445045}, {'id': 'https://openalex.org/C2779829264', 'wikidata': 'https://www.wikidata.org/wiki/Q21011228', 'display_name': 'Dulaglutide', 'level': 5, 'score': 0.9371843}, {'id': 'https://openalex.org/C2909862629', 'wikidata': 'https://www.wikidata.org/wiki/Q27261089', 'display_name': 'Semaglutide', 'level': 5, 'score': 0.9043381}, {'id': 'https://openalex.org/C185280430', 'wikidata': 'https://www.wikidata.org/wiki/Q14909910', 'display_name': 'Glucagon-like peptide 1 receptor', 'level': 4, 'score': 0.7604935}, {'id': 'https://openalex.org/C2777180221', 'wikidata': 'https://www.wikidata.org/wiki/Q3025883', 'display_name': 'Type 2 diabetes', 'level': 3, 'score': 0.6867969}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.471252}, {'id': 'https://openalex.org/C2776398474', 'wikidata': 'https://www.wikidata.org/wiki/Q424611', 'display_name': 'Glucagon-like peptide-1', 'level': 4, 'score': 0.44133228}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.369703}, {'id': 'https://openalex.org/C2778938600', 'wikidata': 'https://www.wikidata.org/wiki/Q389934', 'display_name': 'Agonist', 'level': 3, 'score': 0.31101575}, {'id': 'https://openalex.org/C555293320', 'wikidata': 'https://www.wikidata.org/wiki/Q12206', 'display_name': 'Diabetes mellitus', 'level': 2, 'score': 0.2932675}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.2680216}, {'id': 'https://openalex.org/C134018914', 'wikidata': 'https://www.wikidata.org/wiki/Q162606', 'display_name': 'Endocrinology', 'level': 1, 'score': 0.22400257}], 'mesh': [{'descriptor_ui': 'D003924', 'descriptor_name': 'Diabetes Mellitus, Type 2', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000067757', 'descriptor_name': 'Glucagon-Like Peptide-1 Receptor', 'qualifier_ui': 'Q000819', 'qualifier_name': 'agonists', 'is_major_topic': True}, {'descriptor_ui': 'D007004', 'descriptor_name': 'Hypoglycemic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D003924', 'descriptor_name': 'Diabetes Mellitus, Type 2', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077270', 'descriptor_name': 'Exenatide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000067757', 'descriptor_name': 'Glucagon-Like Peptide-1 Receptor', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004763', 'descriptor_name': 'Glucagon-Like Peptides', 'qualifier_ui': 'Q000031', 'qualifier_name': 'analogs & derivatives', 'is_major_topic': False}, {'descriptor_ui': 'D004763', 'descriptor_name': 'Glucagon-Like Peptides', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D004763', 'descriptor_name': 'Glucagon-Like Peptides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007004', 'descriptor_name': 'Hypoglycemic Agents', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D007004', 'descriptor_name': 'Hypoglycemic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007141', 'descriptor_name': 'Immunoglobulin Fc Fragments', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D007141', 'descriptor_name': 'Immunoglobulin Fc Fragments', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069450', 'descriptor_name': 'Liraglutide', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000069450', 'descriptor_name': 'Liraglutide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010455', 'descriptor_name': 'Peptides', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D010455', 'descriptor_name': 'Peptides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011993', 'descriptor_name': 'Recombinant Fusion Proteins', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D011993', 'descriptor_name': 'Recombinant Fusion Proteins', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014688', 'descriptor_name': 'Venoms', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D014688', 'descriptor_name': 'Venoms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28991932', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.84, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4289779349', 'https://openalex.org/W4232362753', 'https://openalex.org/W3195538090', 'https://openalex.org/W2992144798', 'https://openalex.org/W2979558564', 'https://openalex.org/W2976394260', 'https://openalex.org/W2963614034', 'https://openalex.org/W2592545469', 'https://openalex.org/W2555863893', 'https://openalex.org/W2490399744'], 'abstract_inverted_index': {'Since': [0], '2005,': [1], 'four': [2], 'new': [3], 'GLP-1RAs': [4], '(liraglutide,': [5], 'albiglutide,': [6], 'dulaglutide,': [7], 'and': [8, 10], 'lixisenatide)': [9], 'a': [11], 'once-weekly': [12], 'formulation': [13], 'of': [14, 21], 'exenatide': [15, 36], 'were': [16], 'approved': [17], 'for': [18], 'the': [19, 32], 'treatment': [20], 'persons': [22], 'with': [23], 'T2DM.': [24], 'Another': [25], 'GLP-1RA,': [26], 'semaglutide,': [27], 'is': [28, 35], 'under': [29], 'review': [30], 'by': [31], 'FDA,': [33], 'as': [34], 'administered': [37], 'via': [38], 'an': [39], 'osmotic': [40], 'mini-pump.': [41]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2976394260', 'counts_by_year': [], 'updated_date': '2024-12-06T21:55:20.223663', 'created_date': '2019-10-03'}